Lyra Therapeutics, Inc. LYRA

Company Overview

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of localized, long-acting therapies for the treatment of chronic diseases of the ear, nose, and throat. The company operates within the biopharmaceutical and medical device–enabled drug delivery industries, with a primary emphasis on chronic rhinosinusitis (CRS), a large and underserved inflammatory disease market. Lyra does not currently have FDA-approved commercial products and does not generate product revenue.

The company’s core value proposition is its proprietary XTreo™ drug delivery platform, which is designed to provide sustained, localized drug release directly to sinonasal tissues. Lyra’s lead product candidates, including LYR‑210 and LYR‑220, are bioresorbable nasal implants intended to deliver anti-inflammatory medication over extended periods. Lyra Therapeutics was founded in 2005 and has evolved from early biomaterials research into a focused clinical-stage company advancing late-stage CRS programs, culminating in its public listing on Nasdaq under the ticker LYRA.